EGFR and colorectal cancer: In patients with colorectal cancer (n = 67,959), the HRs for ATE were 1.25 (95% CI: 1.02–1.52) with VEGF-targeted therapy (n = 6769) and 1.38 (95% CI: 1.07–1.79) with EGFR-targeted therapy (n = 3932).